Differential effects of ketoconazole on exposure to temsirolimus following intravenous infusion of temsirolimus

British Journal of Cancer

Volumn 98, Issue 11, 2008, Pages 1797-1802

  Boni, J P ^a   Leister, C ^a   Burns, J ^a   Hug, B ^a  

^a PFIZER INC   (United States)

Author keywords

CYP3A4; Cytochrome P450; Ketoconazole; Pharmacokinetics; Temsirolimus

Indexed keywords

CYTOCHROME P450 3A4; KETOCONAZOLE; RAPAMYCIN; TEMSIROLIMUS;

ADULT; APHTHOUS STOMATITIS; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CHILL; CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; DYSPEPSIA; EPISTAXIS; FEMALE; GRANULOCYTOSIS; HEADACHE; HERPES SIMPLEX; HOSTILITY; HUMAN; INSOMNIA; MALE; MONOTHERAPY; MOUTH PAIN; MUSCLE TWITCH; NAUSEA; NECK PAIN; NERVOUSNESS; NEUTROPENIA; NORMAL HUMAN; PAIN; PRIORITY JOURNAL; RASH; RHINITIS; SIDE EFFECT; SINUS TACHYCARDIA; SYNCOPE; TREMOR; VASCULAR HEADACHE; VISUAL FIELD DEFECT; XEROSTOMIA;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; CYTOCHROME P-450 CYP3A; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; KETOCONAZOLE; MALE; MIDDLE AGED; SIROLIMUS;

EID: 44349099754     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604376     Document Type: Article

References (22)

1. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22: 909-918
2. Berezhkovskiy LM (2004) Determination of volume of distribution at steady state with complete consideration of the kinetics of protein and tissue binding in linear pharmacokinetics. J Pharm Sci 93: 364-374
3. Boni J, Leister C, Burns J, Cincotta M, Hug B, Moore L (2007) Pharmacokinetic profile of temsirolimus with concomitant administration of cytochrome P450-inducing medications. J Clin Pharmacol 47: 1430-1439
4. Boni JP, Leister C, Bender G, Fitzpatrick V, Twine N, Stover J, Dorner A, Immermann F, Burczynski ME (2005) Population pharmacokinetics of CCI-779: correlations to safety and pharmacogenomic responses in patients with advanced renal cancer. Clin Pharmacol Ther 77: 76-89
5. Cai P, Tsao R, Ruppen ME (2007) In vitro metabolic study of temsirolimus: preparation, isolation, and identification of the metabolites. Drug Metab Dispos 35: 1554-1563
6. Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De AL, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Dancey J, Prados MD (2005) Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23: 357-361
7. Dresser GK, Spence JD, Bailey DG (2000) Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 38: 41-57
8. El-Dahshan KF, Bakr MA, Donia AF, Badr A, Sobh MA (2006) Ketoconazole-tacrolimus coadministration in kidney transplant recipients: two-year results of a prospective randomized study. Am J Nephrol 26: 293-298
9. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, Blenis J (2004) mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4E-BP1/eukaryotic translation initiation factor 4E. Mol Cell Biol 24: 200-216
10. Hidalgo M, Buckner JC, Erlichman C, Pollack MS, Boni JP, Dukart G, Marshall B, Speicher L, Moore L, Rowinsky EK (2006) A phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 12: 5755-5763
11. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf I, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer R, Global ARCC Trial (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271-2281
12. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ, Abraham RT (2002) Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22: 7004-7014
13. Jusko WJ (1992) Guidelines for collection and analysis of pharmacokinetic data. In Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, Evans WE, Schentag JJ, Jusko WJ (eds) pp 2.1-2.43. Applied Therapeutics Inc: Vancouver, Wash
14. Kovarik JM, Beyer D, Bizot MN, Jiang Q, Shenouda M, Schmouder RL (2005) Blood concentrations of everolimus are markedly increased by ketoconazole. J Clin Pharmacol 45: 514-518
15. Kovarik JM, Beyer D, Schmouder RL (2006) Everolimus drug interactions: application of a classification system for clinical decision making. Biopharm Drug Dispos 27: 421-426
16. Li AP, Kaminski DL, Rasmussen A (1995) Substrates of human hepatic cytochrome P450 3A4. Toxicology 104: 1-8
17. Punt CJ, Boni J, Bruntsch U, Peters M, Thielert C (2003) Phase I and pharmacokinetic study of CCI-779, a novel cytostatic cell-cycle inhibitor, in combination with 5-fluorouracil and leucovorin in patients with advanced solid tumors. Ann Oncol 14: 931-937
18. Schmelzle T, Hall MN (2000) TOR, a central controller of cell growth. Cell 103: 253-262
19. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: 414-423
20. Skotnicki JS, Leone CL, Smith AL, Palmer YL, Yu K, Discafani CM, Gibbons JJ, Frost P, Abou-Gharbia MA (2001) Design, synthesis and biological evaluation of C-42 hydroxyesters of rapamycin: the identification of CCI-779 [abstract 477]. Clin Cancer Res 7: 3749S-3750S
21. Torisel [package insert] (2007). Wyeth Pharmaceuticals Inc.: Philadelphia, PA
22. Zimmerman JJ (2004) Exposure-response relationships and drug interactions of sirolimus. AAPS J 6: e28